Kent Lehman, MD
Family Medicine · Berne, INNPI 1619905395
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 150 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $604 and has fallen 63.8% since, to $219 in 2025.
Across 150 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$612
- AstraZeneca$320
- Novo Nordisk$290
- Amarin Pharma, Inc.$182
- Sanofi-aventis U.S. LLC$162
- Boehringer Ingelheim$114
- plus $928 from 21 others
Across 36 payments — averaging $1407.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$51K
What the payments were for
- Food & beverage$2,55998%
- Education$502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 30 | $612 |
| AstraZeneca | 18 | $320 |
| Novo Nordisk | 17 | $290 |
| Amarin Pharma, Inc. | 10 | $182 |
| Sanofi-aventis U.S. LLC | 10 | $162 |
| Boehringer Ingelheim | 8 | $114 |
| Kowa Pharmaceuticals America, Inc. | 7 | $101 |
| GSK | 6 | $98 |
| Bayer | 4 | $93 |
| AbbVie | 5 | $91 |
| Pfizer | 3 | $73 |
| E.r. Squibb & Sons, L.L.C. | 4 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $59 |
| Idorsia Pharmaceuticals US Inc | 3 | $48 |
| Esperion Therapeutics, Inc. | 3 | $38 |
| Corcept Therapeutics | 2 | $37 |
| Eisai Inc. | 2 | $37 |
| Astellas Pharma US Inc | 2 | $32 |
| Abbott | 2 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Travere Therapeutics, Inc. | 4 | $17 |
| Exact Sciences | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Merck | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$2,609 in reported general payments places this provider in the 75th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 204 | $218,537 |
| EliquisApixaban | 184 | $120,079 |
| JardianceEmpagliflozin | 90 | $59,537 |
| OzempicSemaglutide | 55 | $59,495 |
| FarxigaDapagliflozin Propanediol | 99 | $58,873 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $39,222 |
| XareltoRivaroxaban | 34 | $28,711 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 21 | $25,132 |
| TradjentaLinagliptin | 46 | $20,597 |
| VascepaIcosapent Ethyl | 20 | $16,051 |
| Breo ElliptaFluticasone/Vilanterol | 44 | $15,556 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $12,477 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $10,518 |
| LivaloPitavastatin Calcium | 17 | $10,381 |
| SynthroidLevothyroxine Sodium | 92 | $9,970 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $612 | $218,537204 claims |
| PfizerEliquis | $73 | $120,079184 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $290 | $84,62776 claims |
| Boehringer IngelheimJardiance, Tradjenta | $114 | $80,133136 claims |
| AstraZenecaFarxiga, Symbicort, Pulmicort Flexhaler | $320 | $65,569127 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $98 | $54,778101 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $101 | $10,38117 claims |
| AbbVieSynthroid | $91 | $9,97092 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $162 | $9,12440 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Berne
- Richard TannerIndianapolis$1.6M
- James AndryBloomington$715K
- Richard FeldmanIndianapolis$476K
- Anthony InzerelloEvansville$308K
- Joe BanksIndianapolis$294K
- Steven GatewoodElwood$281K
- Shekar PushpalaCarmel$239K
- Victoria MoyerKokomo$188K
- Thomas KintanarFort Wayne$185K
- Jeffrey HiltzMuncie$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.